Suppr超能文献

贝尔面瘫的疼痛病程:泼尼松龙和伐昔洛韦治疗

The course of pain in Bell's palsy: treatment with prednisolone and valacyclovir.

作者信息

Berg Thomas, Axelsson Sara, Engström Mats, Stjernquist-Desatnik Anna, Pitkäranta Anne, Kanerva Mervi, Jonsson Lars

机构信息

Department of Plastic and Reconstructive Surgery, Uppsala University Hospital, Uppsala, Sweden.

出版信息

Otol Neurotol. 2009 Sep;30(6):842-6. doi: 10.1097/MAO.0b013e3181ab31c8.

Abstract

OBJECTIVE

To evaluate the effect of prednisolone and valacyclovir on ipsilateral pain around the ear and in the face or neck in Bell's palsy. The incidence and intensity of pain during the first 2 months of palsy and its prognostic value were also assessed.

STUDY DESIGN

Prospective, randomized, double-blind, placebo-controlled, multicenter trial.

SETTING

Sixteen tertiary referral centers in Sweden and 1 in Finland.

PATIENTS

Data are part of the Scandinavian Bell's palsy study; 829 patients aged 18 to 75 years with onset of palsy within 72 hours were included. Follow-up time was 12 months.

INTERVENTION

Patients were assigned to 1 of 4 treatment arms in a factorial fashion: placebo plus placebo; prednisolone 60 mg daily for 5 days, then tapering for 5 days, plus placebo; valacyclovir 1,000 mg 3 times daily for 7 days plus placebo; or prednisolone plus valacyclovir.

MAIN OUTCOME MEASURES

Pain was registered on a visual analog scale within 72 hours, at Days 11 to 17, 1 month, and 2 months. Facial function was assessed with the Sunnybrook and House-Brackmann systems.

RESULTS

Prednisolone and/or valacyclovir did not significantly affect the incidence or intensity of pain during the first 2 months. Pain was registered in 542 (65%) of 829 patients. At 2 months, 53 (8%) of 637 patients still reported pain. Subjects with pain at Days 11 to 17 had lower facial recovery rates at 12 months than those with no pain (p < 0.0001).

CONCLUSION

Prednisolone and/or valacyclovir did not affect the incidence or intensity of ipsilateral pain in Bell's palsy. The incidence of pain was similar during the first 2 weeks and then decreased. Presence of pain at Days 11 to 17 indicated a worse prognosis for facial recovery.

摘要

目的

评估泼尼松龙和伐昔洛韦对贝尔面瘫患者耳部周围及面部或颈部同侧疼痛的影响。同时评估面瘫前2个月内疼痛的发生率、强度及其预后价值。

研究设计

前瞻性、随机、双盲、安慰剂对照、多中心试验。

研究地点

瑞典的16个三级转诊中心和芬兰的1个中心。

患者

数据来自斯堪的纳维亚贝尔面瘫研究;纳入了829例年龄在18至75岁之间、面瘫发作在72小时内的患者。随访时间为12个月。

干预措施

患者以析因方式被分配到4个治疗组之一:安慰剂加安慰剂;泼尼松龙每日60毫克,服用5天,然后逐渐减量5天,加安慰剂;伐昔洛韦每日1000毫克,分3次服用,共7天,加安慰剂;或泼尼松龙加伐昔洛韦。

主要观察指标

在72小时内、第11至17天、1个月和2个月时,通过视觉模拟量表记录疼痛情况。采用桑尼布鲁克和豪斯-布拉克曼系统对面部功能进行评估。

结果

泼尼松龙和/或伐昔洛韦在前2个月内对疼痛的发生率或强度没有显著影响。829例患者中有542例(65%)出现疼痛。在2个月时,637例患者中有53例(8%)仍报告有疼痛。在第11至17天有疼痛的受试者在12个月时的面部恢复率低于无疼痛者(p<0.0001)。

结论

泼尼松龙和/或伐昔洛韦不影响贝尔面瘫同侧疼痛的发生率或强度。疼痛发生率在前2周相似,然后下降。在第11至17天出现疼痛表明面部恢复预后较差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验